JP2020075913A - ストレス耐性付与組成物、ストレス耐性付与方法、ストレス耐性体内増殖方法、及びストレス評価方法 - Google Patents
ストレス耐性付与組成物、ストレス耐性付与方法、ストレス耐性体内増殖方法、及びストレス評価方法 Download PDFInfo
- Publication number
- JP2020075913A JP2020075913A JP2019193677A JP2019193677A JP2020075913A JP 2020075913 A JP2020075913 A JP 2020075913A JP 2019193677 A JP2019193677 A JP 2019193677A JP 2019193677 A JP2019193677 A JP 2019193677A JP 2020075913 A JP2020075913 A JP 2020075913A
- Authority
- JP
- Japan
- Prior art keywords
- stress
- composition
- resistance
- imparting
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims description 19
- 230000001965 increasing effect Effects 0.000 title claims description 15
- 238000001727 in vivo Methods 0.000 title claims description 14
- 238000011156 evaluation Methods 0.000 title claims description 13
- 229960001682 n-acetyltyrosine Drugs 0.000 claims abstract description 85
- 241000124008 Mammalia Species 0.000 claims abstract description 78
- -1 N-acetyl tyrosine compound Chemical class 0.000 claims abstract description 41
- 230000000694 effects Effects 0.000 claims description 29
- 235000013305 food Nutrition 0.000 claims description 16
- 230000003078 antioxidant effect Effects 0.000 claims description 13
- 230000012010 growth Effects 0.000 claims description 13
- 238000005259 measurement Methods 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 7
- 239000013589 supplement Substances 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 206010059866 Drug resistance Diseases 0.000 claims description 3
- 230000003444 anaesthetic effect Effects 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 230000003340 mental effect Effects 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 2
- 230000035882 stress Effects 0.000 description 167
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 27
- 241000282414 Homo sapiens Species 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 206010009944 Colon cancer Diseases 0.000 description 16
- 208000029742 colonic neoplasm Diseases 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000008642 heat stress Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 231100000652 hormesis Toxicity 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 239000000575 pesticide Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000003313 weakening effect Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019345 Heat stroke Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001477931 Mythimna unipuncta Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000012854 evaluation process Methods 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229950010617 oxfenicine Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000024241 parasitism Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- SKAWDTAMLOJQNK-UHFFFAOYSA-N 2-acetamido-3-(4-hydroxyphenyl)propanoic acid ethyl ester Chemical compound CCOC(=O)C(NC(C)=O)CC1=CC=C(O)C=C1 SKAWDTAMLOJQNK-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 101150046266 foxo gene Proteins 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 125000004436 sodium atom Chemical group 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
また、ストレス依存的なN−アセチルチロシン及び/又はその類縁体の血中濃度上昇が確認されたことから、血中でのN−アセチルチロシン及び/又はその類縁体の定量によって、ヒトのストレス度調査を可能になることを見出した。すなわち、当該組成物を用いることによって、ストレス耐性を付与する各種の方法及びストレスを評価する方法も見出した。
本願の第1の実施形態に係るストレス耐性付与組成物は、哺乳類にストレス耐性を付与するためのストレス耐性付与組成物であって、N−アセチルチロシン化合物及び/又はその類縁体を含むものである。
本願の第2の実施形態は、上述した第1の実施形態に記載したストレス耐性付与組成物を用いたストレス耐性付与方法として、当該ストレス耐性付与組成物を前記哺乳類に導入する導入工程を含むものである。
本願の第3の実施形態は、上述した第1の実施形態に記載したストレス耐性付与組成物として哺乳類中のN−アセチルチロシン化合物及び/又はその類縁体を、前記哺乳類の体内で増加させて、ストレス耐性を増殖させるストレス耐性体内増殖方法であって、前記哺乳類にストレスを付加するストレス付加工程を含むストレス耐性体内増殖方法である。
本願の第4の実施形態は、上述した第1の実施形態に記載したストレス耐性付与組成物を用いるストレス評価方法であり、このストレス耐性付与組成物の含有量として前記哺乳類中のN−アセチルチロシン化合物及び/又はその類縁体の含有量を測定する測定工程と、前記含有量に基づいて、前記哺乳類が受けているストレスの度合いを評価する評価工程を含むものである。
先ず、図1(a)に示すように、測定工程では、このストレス耐性付与組成物の含有量として前記哺乳類中のN−アセチルチロシン化合物及び/又はその類縁体の含有量を測定する。測定方法としては、哺乳類から血液採取などを行い、採取した血液中のN−アセチルチロシン化合物及び/又はその類縁体の含有量(または濃度)を測定する(S1)。測定方法としては、比色定量分析や液体高速クロマトグラフィーを用いる分析等、考え得る全ての分析方法を含む。
次に、評価工程では、前記測定工程で測定された前記含有量に基づいて、前記哺乳類が受けているストレスの度合いを評価する。この評価方法としては、先ず、ストレスの基準値として前記含有量の閾値を定める。この閾値としては、例えば、ストレスが無い平常時の前記哺乳類における前記含有量の平均値を用いることができる。次に、前記含有量と、この閾値との大小関係を比較する(S2)。
マウスに対して、異なる濃度(1個体あたり0.2g/kg、1.0g/kg、および0モル(リン酸緩衝生理食塩水(PBS):比較例))のN−アセチルチロシンを飲用飼料として投与して以下のように各サンプルを得た。
・ケージ:ポリオレフィン(TPX)製ケージ(180×240×130mm、日本クレア(株))
・収容匹数/ケージ:1匹/ケージ
・ケージ交換頻度:週1回の頻度で交換。
マウスに対して、N−アセチルチロシンのW14固形がん成長に対する効果を確認した。以下のような実験をヌードマウスを用いて行った。
1)細胞;ラット胎児由来繊維芽細胞にH-rasがん遺伝子を移入して形質を転換させたW14細胞を使用した。
2)スケジュールは、実験開始1週間前から0.5g/kgのN−アセチルチロシンを飲水(飲用飼料として投与)させ、1週間後、W14細胞を105 cells/mouse(マウス1匹当たり105細胞)で皮下に注入した。
3)その後、固形がんの成長を計測した。
熱ストレス負荷によるヒト血清中のN−アセチルチロシン定量実験を行った。先ず、市販の血清を使用して、N−アセチルチロシンを測定した結果を図5(a)に示す。得られた結果から、ヒトの血清中に、N−アセチルチロシンが存在することが確認された。
ストレス耐性付与組成物であるN−アセチルチロシンについて、ヒト大腸がんHCT116細胞を用いた大腸がん細胞増殖抑制効果を確認した。
N−アセチルチロシンの誘導体として、N−アセチル−L−(4−ヒドロフェニル)グリシン(N-acetyl L-(4-hydrophenyl)glycine)(別名: N−アセチル−オクスフェニシン(N-acetyl Oxfenicine))を用いて、アワヨトウ幼虫に対してストレス緩和活性を確認した。
上記実施例5で用いたストレス耐性付与組成物であるN−アセチル−オクスフェニシン(N-acetyloxfenicine)について、ヒト大腸がんHCT116細胞を用いた大腸がん細胞増殖抑制効果を確認した。
Claims (7)
- 哺乳類にストレス耐性を付与するためのストレス耐性付与組成物であって、
N−アセチルチロシン化合物及び/又はその類縁体を含むことを特徴とする
ストレス耐性付与組成物。 - 請求項1に記載のストレス耐性付与組成物において、
前記ストレス耐性が、温度抵抗性、薬剤抵抗性、感染抵抗性、寄生抵抗性、傷害抵抗性、及び精神的ストレス抵抗性から成る群より選択される少なくとも1つの抵抗性であることを特徴とする
ストレス耐性付与組成物。 - 請求項1又は請求項2に記載のストレス耐性付与組成物において、
前記ストレス耐性が、抗酸化酵素の活性を制御することによって付与されることを特徴とする
ストレス耐性付与組成物。 - 請求項1〜請求項3のいずれかに記載のストレス耐性付与組成物において、
哺乳類に投与開始後、所定時間放置することを特徴とする
ストレス耐性付与組成物。 - 請求項1〜請求項4のいずれかに記載のストレス耐性付与組成物を含有する食品組成物であって、
サプリメント、健康補助食品、栄養機能食品、機能性表示食品、特別用途食品、特定保健用食品、栄養補助食品、麻酔液、又は飲料であることを特徴とする
食品組成物。 - 請求項1〜請求項4のいずれかに記載のストレス耐性付与組成物として哺乳類中のN−アセチルチロシン化合物及び/又はその類縁体を、前記哺乳類の体内で増加させて、ストレス耐性を増殖させるストレス耐性体内増殖方法であって、
前記哺乳類にストレスを付加するストレス付加工程を含むことを特徴とする
ストレス耐性体内増殖方法。 - 請求項1〜請求項4のいずれかに記載のストレス耐性付与組成物の含有量として前記哺乳類中のN−アセチルチロシン化合物及び/又はその類縁体の含有量を測定する測定工程と、
前記含有量に基づいて、前記哺乳類が受けているストレスの度合いを評価する評価工程を含むことを特徴とする
ストレス評価方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018208265 | 2018-11-05 | ||
JP2018208265 | 2018-11-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020075913A true JP2020075913A (ja) | 2020-05-21 |
JP6799870B2 JP6799870B2 (ja) | 2020-12-16 |
Family
ID=70723465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019193677A Expired - Fee Related JP6799870B2 (ja) | 2018-11-05 | 2019-10-24 | ストレス耐性付与組成物、ストレス耐性付与方法、ストレス耐性体内増殖方法、及びストレス評価方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6799870B2 (ja) |
-
2019
- 2019-10-24 JP JP2019193677A patent/JP6799870B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP6799870B2 (ja) | 2020-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Todoriuk et al. | Preclinical research of the experimental preparation “Ferosel T” | |
Reid et al. | Kupffer cells undergo fundamental changes during the development of experimental NASH and are critical in initiating liver damage and inflammation | |
Morera et al. | Chronic heat stress up-regulates leptin and adiponectin secretion and expression and improves leptin, adiponectin and insulin sensitivity in mice | |
Close et al. | Recommendations for euthanasia of experimental animals: Part 2 | |
Ekundi‐Valentim et al. | Differing effects of exogenous and endogenous hydrogen sulphide in carrageenan‐induced knee joint synovitis in the rat | |
Tuerke et al. | Double dissociation between regulation of conditioned disgust and taste avoidance by serotonin availability at the 5-HT3 receptor in the posterior and anterior insular cortex | |
Torres‐Espín et al. | Bone marrow mesenchymal stromal cells and olfactory ensheathing cells transplantation after spinal cord injury–a morphological and functional comparison in rats | |
Fujiwara et al. | Altered pressure-natriuresis in obese Zucker rats | |
Yabuki et al. | Oral L-citrulline administration improves memory deficits following transient brain ischemia through cerebrovascular protection | |
Niemann et al. | An mtDNA mutation accelerates liver aging by interfering with the ROS response and mitochondrial life cycle | |
Shepard et al. | Pharmacodynamics of alfaxalone after single‐dose intramuscular administration in red‐eared sliders (Trachemys scripta elegans): a comparison of two different doses at two different ambient temperatures | |
Zhang et al. | Cardiac overexpression of insulin-like growth factor 1 attenuates chronic alcohol intake-induced myocardial contractile dysfunction but not hypertrophy: roles of Akt, mTOR, GSK3β, and PTEN | |
Wang et al. | Effects of dietary tributyrin on intestinal mucosa development, mitochondrial function and AMPK-mTOR pathway in weaned pigs | |
Olsson et al. | Comparison of biochemical stress indicators in juvenile captive estuarine crocodiles (Crocodylus porosus) following physical restraint or chemical restraint by midazolam injection | |
Guarino et al. | Frustrative nonreward: Chemogenetic inactivation of the central amygdala abolishes the effect of reward downshift without affecting alcohol intake | |
Farahpour et al. | Effect of in situ delivery of acetyl-L-carnitine on peripheral nerve regeneration and functional recovery in transected sciatic nerve in rat | |
Marinho et al. | Rosuvastatin limits the activation of hepatic stellate cells in diet‐induced obese mice | |
Yang et al. | Interactions among ovarian hormones and time of testing on behavioral sensitization and cocaine self-administration | |
Nikolaevsky et al. | Hepatotropic, antioxidant and antitoxic action of amaranth oil | |
JP6799870B2 (ja) | ストレス耐性付与組成物、ストレス耐性付与方法、ストレス耐性体内増殖方法、及びストレス評価方法 | |
Schwedhelm et al. | Experimentally induced hyperchloremic and DL-lactic acidosis in calves: An attempt to study the effects of oral rehydration on acid-base status | |
Emami et al. | Effects of high intensity interval training and curcumin supplement on glutathione peroxidase (GPX) activity and malondialdehyde (MDA) concentration of the liver in STZ induced diabetic rats | |
Cleale et al. | Pharmacokinetic and pharmacodynamic evaluation of propofol administered to cats in a novel, aqueous, nano‐droplet formulation or as an oil‐in‐water macroemulsion 1 | |
JP6650053B2 (ja) | ブチリデンフタリドの用途 | |
Pautassi et al. | Acute ethanol counteracts the acquisition of aversive olfactory learning in infant rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200123 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200123 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200206 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200513 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200707 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200923 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200923 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201002 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201013 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201116 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6799870 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |